PL1492519T3 - Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich - Google Patents

Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich

Info

Publication number
PL1492519T3
PL1492519T3 PL04757949T PL04757949T PL1492519T3 PL 1492519 T3 PL1492519 T3 PL 1492519T3 PL 04757949 T PL04757949 T PL 04757949T PL 04757949 T PL04757949 T PL 04757949T PL 1492519 T3 PL1492519 T3 PL 1492519T3
Authority
PL
Poland
Prior art keywords
calcium channel
compounds
channel modulators
antimuscarinics
urinary tract
Prior art date
Application number
PL04757949T
Other languages
English (en)
Inventor
Matthew Oliver Fraser
Karl Bruce Thor
Edward C Burgard
Lee R Brettman
Steven B Landau
Daniel J Ricca
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Publication of PL1492519T3 publication Critical patent/PL1492519T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
PL04757949T 2003-03-21 2004-03-22 Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich PL1492519T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45683503P 2003-03-21 2003-03-21
US48614803P 2003-07-10 2003-07-10
US50957003P 2003-10-08 2003-10-08
US53487104P 2004-01-08 2004-01-08
US54825004P 2004-02-27 2004-02-27
PCT/US2004/008605 WO2004084879A1 (en) 2003-03-21 2004-03-22 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
EP04757949A EP1492519B1 (en) 2003-03-21 2004-03-22 Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators

Publications (1)

Publication Number Publication Date
PL1492519T3 true PL1492519T3 (pl) 2007-04-30

Family

ID=33102559

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04757949T PL1492519T3 (pl) 2003-03-21 2004-03-22 Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich
PL378583A PL378583A1 (pl) 2003-03-21 2004-03-22 Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL378583A PL378583A1 (pl) 2003-03-21 2004-03-22 Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych

Country Status (14)

Country Link
US (7) US20040198822A1 (pl)
EP (2) EP1721607A1 (pl)
JP (1) JP2006520799A (pl)
KR (1) KR100742001B1 (pl)
CN (1) CN1791399A (pl)
AT (1) ATE345120T1 (pl)
AU (1) AU2004224322A1 (pl)
BR (1) BRPI0408608A (pl)
CA (1) CA2519694A1 (pl)
DE (1) DE602004003172T2 (pl)
DK (1) DK1492519T3 (pl)
ES (1) ES2275229T3 (pl)
PL (2) PL1492519T3 (pl)
WO (1) WO2004084879A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843303B1 (fr) * 2002-08-07 2006-01-21 R & D Pharma Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
EP1621193A3 (en) * 2002-12-20 2006-08-02 Dynogen Pharmaceuticals Inc. Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
JP2007505149A (ja) 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005092889A1 (ja) * 2004-03-25 2005-10-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の固形製剤用組成物
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20070135377A1 (en) * 2004-12-10 2007-06-14 Roman Stephen B Thixotropic anti-viral formulation
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
KR101312814B1 (ko) * 2005-02-03 2013-09-27 오노 야꾸힝 고교 가부시키가이샤 경피 흡수형 제제
US20060217405A1 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
WO2007005780A2 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EP1741444A1 (en) * 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
CN104069567A (zh) 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
WO2008151092A1 (en) * 2007-05-30 2008-12-11 Microdose Therapeutx Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2008157205A2 (en) * 2007-06-15 2008-12-24 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
WO2009151613A1 (en) * 2008-06-13 2009-12-17 Concert Pharmaceuticals, Inc. Oxybutynin derivatives
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
US8991390B2 (en) 2010-01-05 2015-03-31 Microdose Therapeutx, Inc. Inhalation device and method
US8377956B2 (en) 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2612663A1 (en) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20180023057A (ko) * 2012-01-04 2018-03-06 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
EP2612662B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Delayed-release formulation for reducing the frequency of urination and method of use thereof
MY173582A (en) * 2012-01-04 2020-02-04 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ630471A (en) * 2012-03-19 2016-04-29 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
EP2897535A4 (en) * 2012-09-24 2016-06-22 Cormatrix Cardiovascular Inc INJECTION DEVICE WITH MULTIPLE NEEDLES AND SYSTEM FOR THE DISTRIBUTION OF PHARMACOLOGICAL ACTIVE SUBSTANCES TO BIOLOGICAL TISSUE
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine
EP3183274B1 (en) 2014-08-22 2018-05-02 KOC Universitesi A ph responsive hybrid hydrogel and method of synthesis thereof
WO2016028237A1 (en) * 2014-08-22 2016-02-25 Koç Üniversitesi A novel ph responsive hydrogel and method of synthesis
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
CN109310651A (zh) * 2016-05-13 2019-02-05 小利兰·斯坦福大学董事会 肾上腺素能受体调节化合物及其使用方法
WO2018071434A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
AU2018260699B2 (en) 2017-04-26 2022-04-28 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
WO2018215381A2 (en) * 2017-05-26 2018-11-29 Novassay Sa Voltage-gated calcium channel auxilliary subunit alpha 2 delta and uses thereof
JP7480131B2 (ja) * 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
KR20200056719A (ko) * 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
WO1995009167A1 (fr) * 1993-09-30 1995-04-06 Tokyo Tanabe Company Limited Derive d'indoline et antagoniste du recepteur 5-ht3 contenant ce derive et utilise comme ingredient actif
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
FR2771093B1 (fr) * 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
EP1082306A1 (en) * 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
ES2341059T3 (es) * 1999-04-08 2010-06-14 Warner-Lambert Company Llc Tratamiento de la incontinencia.
MXPA02000170A (es) * 1999-07-02 2002-07-02 Warner Lambert Co Una combinacion sinergica: gabapentin y pregablin.
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
PT1289364E (pt) * 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
KR100667721B1 (ko) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
SK6092003A3 (en) * 2000-11-30 2004-07-07 Pfizer Prod Inc Combination of GABA agonists and aldosereductase inhibitors
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
KR20100036390A (ko) * 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
CA2476438A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
CA2509605C (en) * 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders

Also Published As

Publication number Publication date
ES2275229T3 (es) 2007-06-01
KR100742001B1 (ko) 2007-07-23
US20070060652A1 (en) 2007-03-15
CN1791399A (zh) 2006-06-21
JP2006520799A (ja) 2006-09-14
AU2004224322A1 (en) 2004-10-07
PL378583A1 (pl) 2006-05-02
CA2519694A1 (en) 2004-10-07
DK1492519T3 (da) 2007-03-05
EP1492519B1 (en) 2006-11-15
US20080085916A1 (en) 2008-04-10
WO2004084879A1 (en) 2004-10-07
US20060247311A1 (en) 2006-11-02
EP1721607A1 (en) 2006-11-15
DE602004003172D1 (de) 2006-12-28
US20110294881A1 (en) 2011-12-01
US20040198822A1 (en) 2004-10-07
US20080275080A1 (en) 2008-11-06
ATE345120T1 (de) 2006-12-15
EP1492519A1 (en) 2005-01-05
BRPI0408608A (pt) 2006-03-07
AU2004224322A2 (en) 2004-10-07
KR20050111784A (ko) 2005-11-28
US20050239890A1 (en) 2005-10-27
DE602004003172T2 (de) 2007-09-27

Similar Documents

Publication Publication Date Title
PL378583A1 (pl) Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
US5866585A (en) Methods of treating tardive dyskinesia using NMDA receptor antagonists
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
EA200501497A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2β-БЕЛКУ
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
AU3084302A (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EP1480631A4 (en) METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING MODULATORS OF THE ALPHA-2-DELTA- CALCIUM CANAL UNIT
Solimeno et al. Knee arthropathy: when things go wrong
Sechi et al. Levetiracetam in stiff-person syndrome
Vinik et al. Diabetic neuropathy
RS20060210A (en) Amino acids with affinity for the alpha2delta-protein
TW200511989A (en) Methods for using amino acids with affinity for the α 2 δ-protein
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
Chung et al. The clinical results of conservative treatment of frozen shoulder using continuous passive motion
WO2003045322A3 (en) Method for treating and preventing pancreatitis
WO2002053139A8 (en) Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
KR20180054636A (ko) 선택적 관절성형술을 받은 환자를 위한 통증 치료용 조성물
DK1660067T3 (da) Fremgangsmåder og materialer til behandling af lidelser forbundet med stofskiftesygdomme
Gholamrezaei et al. Interaction between melatonin and exercise in the spatial memory and learning performance in rats
Ko et al. Surface Mapping of Motor Points of Gastrocnemius and Soleus Muscles.